Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...
FierceBiotech1d
Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts
Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...
Sana Biotechnology’s Promising UP421 Results and Potential Upside: A Buy Rating Affirmed
Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Sana Biotechnology (SANA – Research Report) and keeping the price target ...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared ...
Renal & Urology News1d
Late Eating Tied to Poor Glucose Tolerance
“Late eating is associated with greater consumption of calories mostly from carbohydrates and fats and may lead to prolonged evening postprandial glucose excursions contributing to worse glucose ...
bovnews1d
Sana Biotechnology’s (SANA) Revolutionary Breakthrough Sends Stock Soaring
Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...
Sana Biotechnology Shares Spike Following Successful Transplantation
Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...
Sana Biotechnology upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded Sana Biotechnology (SANA) to Buy from Hold without a price target The company reported positive data indicating Hypoimmune ...
BioWorld1d
Sana soars on favorable type 1 diabetes phase I data
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Diamyd Medical AB (publ): New publication highlights safety and potential benefits of redosing Diamyd precision medicine for Type 1 Diabetes
Diamyd Medical announces the publication of the article titled "Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial" in the peer-reviewed journal Inte ...